Pharmacological Effects of Panduratin A on Renal Cyst Development in In Vitro and In Vivo Models of Polycystic Kidney Disease

Pharmacological Effects of Panduratin A on Renal Cyst Development in In Vitro and In Vivo Models of Polycystic Kidney Disease

Renal cyst expansion in polycystic kidney disease (PKD) involves abnormalities in both cyst-lining-cell proliferation and fluid accumulation. Suppression of these processes may retard the progression of PKD. Evidence suggests that the activation of 5′ AMP-activated protein kinase (AMPK) inhibits cys...

Full description

Bibliographic Details
Main Authors:	Kanlayanee Tonum, Nipitpon Srimai, Napason Chabang, Somsak Fongsupa, Patoomratana Tuchinda, Jacob A. Torres, Thomas Weimbs, Sunhapas Soodvilai
Format:	Article
Language:	English
Published:	MDPI AG 2022-04-01
Series:	International Journal of Molecular Sciences
Subjects:	ADPKD cystogenesis AMP-activated protein kinase (AMPK) cell proliferation cystic fibrosis transmembrane conductance regulator (CFTR) renal fluid secretion
Online Access:	https://www.mdpi.com/1422-0067/23/8/4328

Similar Items

Pinostrobin inhibits renal CFTR-mediated Cl− secretion and retards cyst growth in cell-derived cyst and polycystic kidney disease rats
by: Kanlayanee Tonum, et al.
Published: (2022-04-01)

Panduratin A Derivative Protects against Cisplatin-Induced Apoptosis of Renal Proximal Tubular Cells and Kidney Injury in Mice
by: Penjai Thongnuanjan, et al.
Published: (2021-11-01)

CD74 Promotes Cyst Growth and Renal Fibrosis in Autosomal Dominant Polycystic Kidney Disease
by: Julie Xia Zhou, et al.
Published: (2024-03-01)

Zebrafish Model as a Screen to Prevent Cyst Inflation in Autosomal Dominant Polycystic Kidney Disease
by: Inês Oliveira, et al.
Published: (2021-08-01)

PF‐06409577 inhibits renal cyst progression by concurrently inhibiting the mTOR pathway and CFTR channel activity
by: Limin Su, et al.
Published: (2022-10-01)

Total and Extracellular Vesicle cAMP Contents in Urine Are Associated with Autosomal Dominant Polycystic Kidney Disease (ADPKD) Progression
by: María Lucía Rosenberg, et al.
Published: (2023-08-01)

Elexacaftor Mediates the Rescue of F508del CFTR Functional Expression Interacting with MSD2
by: Roberta Bongiorno, et al.
Published: (2023-08-01)

NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis
by: Chiara Brandas, et al.
Published: (2021-09-01)

Functional Consequences of CFTR Interactions in Cystic Fibrosis
by: Yashaswini Ramananda, et al.
Published: (2024-03-01)

Corneal Refractive Surgery Considerations in Patients with Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator-Related Disorders
by: Moshirfar M, et al.
Published: (2022-11-01)

The zebrafish Kupffer's vesicle as a model system for the molecular mechanisms by which the lack of Polycystin-2 leads to stimulation of CFTR
by: Mónica Roxo-Rosa, et al.
Published: (2015-11-01)

Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review
by: Nikoletta Kapouni, et al.
Published: (2023-03-01)

Efficacy and Safety of Triple Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Patients With Cystic Fibrosis: A Meta-Analysis of Randomized Controlled Trials
by: Yizi Wang, et al.
Published: (2022-03-01)

Effectiveness and Safety of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Children With Cystic Fibrosis: A Meta-Analysis
by: Qiyu Li, et al.
Published: (2022-06-01)

New Therapies Targeting Cystogenesis in Autosomal Polycystic Kidney Disease
by: Maurizio Salvadori, et al.
Published: (2017-07-01)

Gender-Dependent Phenotype in Polycystic Kidney Disease Is Determined by Differential Intracellular Ca<sup>2+</sup> Signals
by: Khaoula Talbi, et al.
Published: (2021-06-01)

Beneficial effects of bempedoic acid treatment in polycystic kidney disease cells and mice
by: Kenneth R. Hallows, et al.
Published: (2022-11-01)

One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies
by: Marjolein M. Ensinck, et al.
Published: (2022-06-01)

Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease
by: A. Lianne Messchendorp, et al.
Published: (2018-12-01)

Autosomal Dominant Polycystic Kidney Disease: Extrarenal Involvement
by: Matteo Righini, et al.
Published: (2024-02-01)

Allicin Facilitates Airway Surface Liquid Hydration by Activation of CFTR
by: Zhuo-Er Qiu, et al.
Published: (2022-06-01)

A Precision Medicine Approach to Optimize Modulator Therapy for Rare CFTR Folding Mutants
by: Guido Veit, et al.
Published: (2021-07-01)

Exploring the Mechanism of Activation of CFTR by Curcuminoids: An Ensemble Docking Study
by: Emanuele Bellacchio
Published: (2023-12-01)

Elexacaftor-Tezacaftor-Ivacaftor in 2 cystic fibrosis adults homozygous for M1101K with end-stage lung disease
by: Winnie M. Leung, et al.
Published: (2023-01-01)

CFTR Modulators: Impact on Fertility, Pregnancy, and Lactation in Women with Cystic Fibrosis
by: Jennifer L. Taylor-Cousar
Published: (2020-08-01)

Cystic Fibrosis: Overview of the Current Development Trends and Innovative Therapeutic Strategies
by: Fahad A. Almughem, et al.
Published: (2020-07-01)

'CFTR-opathies': disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations
by: Knowles Michael R, et al.
Published: (2001-08-01)

Pathways, perspectives and pursuits in polycystic kidney disease
by: Bhaskar L. V. K. S., et al.
Published: (2016-01-01)

Dysfunction in the Cystic Fibrosis Transmembrane Regulator in Chronic Obstructive Pulmonary Disease as a Potential Target for Personalised Medicine
by: Laura Carrasco-Hernández, et al.
Published: (2021-10-01)

Cystic Kidney Diseases That Require a Differential Diagnosis from Autosomal Dominant Polycystic Kidney Disease (ADPKD)
by: Akinari Sekine, et al.
Published: (2022-11-01)

The effect of cystic fibrosis transmembrane conductance regulator modulators on impaired glucose tolerance and cystic fibrosis related diabetes
by: Sana Hasan, et al.
Published: (2022-09-01)

Calcium-induced chloride secretion is decreased by Resveratrol in ileal porcine tissue
by: Susanne Hoppe, et al.
Published: (2018-10-01)

Synthesis and Therapeutic Applications of Iminosugars in Cystic Fibrosis
by: Anna Esposito, et al.
Published: (2020-05-01)

Modifier Factors of Cystic Fibrosis Phenotypes: A Focus on Modifier Genes
by: Julie Mésinèle, et al.
Published: (2022-11-01)

Identification of GLPG/ABBV-2737, a Novel Class of Corrector, Which Exerts Functional Synergy With Other CFTR Modulators
by: Gert de Wilde, et al.
Published: (2019-05-01)

Autosomal Dominant Polycystic Kidney Disease: From Pathophysiology of Cystogenesis to Advances in the Treatment
by: Jana Reiterová, et al.
Published: (2022-03-01)

Quantitative Evaluation of CFTR Pre-mRNA Splicing Dependent on the (TG)mTn Poly-Variant Tract
by: Manuela Sterrantino, et al.
Published: (2021-01-01)

Caffeine intake by patients with autosomal dominant polycystic kidney disease
by: L.C. Vendramini, et al.
Published: (2012-09-01)

Caffeine intake by patients with autosomal dominant polycystic kidney disease
by: L.C. Vendramini, et al.
Published: (2012-09-01)

Next-Generation Sequencing for Screening Analysis of Cystic Fibrosis: Spectrum and Novel Variants in a South–Central Italian Cohort
by: Elisa De Paolis, et al.
Published: (2023-08-01)